- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02842307
Acupuncture for Chemical Therapy Induced Nausea and Vomiting
July 20, 2016 updated by: Yutong Fei, Beijing University of Chinese Medicine
Impact of Acupuncturist Expertise on Clinical Effectiveness for Chemotherapy Induced Nausea and Vomiting in Cancer Patients: a Randomized Controlled Trial
This is an expertise-based randomized controlled trial.
The hypothesis of this study is that the differences in expertise of acupuncturist may impact clinical effect.
In this study, patients will be randomized to 4 group, receiving the treatment from senior acupuncturist, junior acupuncturist, junior acupuncturist by only acupuncture Neiguan(P6), or not receive the acupuncture.
All patients receive the basic cisplatin chemotherapy.
The duration of treatment is from the first day receiving cisplatin until two days after cisplatin on each group.
NCI and Rhode scale will be used to measure the control of nausea and vomiting.
Study Overview
Status
Completed
Conditions
Detailed Description
This is an expertise-based randomized controlled trial.
The hypothesis of this study is that the differences in expertise of acupuncturist may impact clinical effect.
In this study, 102 patients will be randomly divided into 4 groups which separately receiving the treatment from senior acupuncturist(clinical experience> 15 years, considered in this trial as highly expertised), junior acupuncturist(clinical experience< 5 years, considered in this trial as lower expertised), junior acupuncturist only acupuncture Neiguan(P6), or not receiving the acupuncture.
All participants receive the cisplatin-based chemotherapy and 5-HT3 as antiemetic treatment will be included.
Acupuncture treatments are given once daily, the duration of treatment is from the first day receiving cisplatin until two days after cisplatin.
NCI and Rhode scale will be used to measure the control of nausea and vomiting.
only outcome assessors are blinded.
Generalized estimating equations will be used to compare the effects among groups.
Study Type
Interventional
Enrollment (Actual)
102
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China, 100091
- Xiyuan Hospital, China Academy of Chinese Medical Sciences
-
-
Beijing
-
Beijing, Beijing, China, 100007
- Dongzhimen Hospital, Beijing University of Chinese Medicine
-
Beijing, Beijing, China, 100053
- Guanganmen Hospital,China Academy of Chinese Medical Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Confirmed diagnosis of cancer
- Must receive cancer chemotherapy containing cisplatin
- Use 5-TH receptor antagonists as an antiemetic drug in the chemotherapy duration
Exclusion Criteria:
- Concurrent neoplasms or illness that induces nausea independent of chemotherapy
- Received acupuncture treatments for other conditions less than 4 weeks before chemotherapy treatment
- Severe infection
- Severe heart, liver, kidney and brain diseases
- Cardiac pacemaker
- Radiotherapy or hormone therapy during chemotherapy treatments
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: A(senior acupuncturists)
Manual acupuncture implemented by senior acupuncturists (clinical experience >15 years)
|
Manual acupuncture once per day.
No limitation on points, manipulations and time per session.
Senior acupuncturists have to have more than 15 years of acupuncture clinical practice experience.
Other Names:
|
|
Active Comparator: B(junior acupuncturists)
Manual acupuncture implemented by junior acupuncturists (clinical experience <5 years)
|
Manual acupuncture once per day.
No limitation on points, manipulations and time per session.
Junior acupuncturists have to have less than 5 years of acupuncture clinical practice experience.
Other Names:
|
|
Active Comparator: C(P6 points)
Manual acupuncture on P6 points by junior acupuncturists (clinical experience <5 years)
|
Manual acupuncture implemented by junior acupuncturists once per day.
P6 point, bilaterally, should achieve deqi sensation by even manipulations.
Junior acupuncturists have to have less than 5 years of acupuncture clinical practice experience.
Other Names:
|
|
No Intervention: D(no acupuncture)
No acupuncture treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
NCI nausea and vomiting rating scale
Time Frame: From the first day receiving cisplatin until two days after cisplatin in each group
|
From the first day receiving cisplatin until two days after cisplatin in each group
|
|
Rhodes Scale
Time Frame: From the first day receiving cisplatin until two days after cisplatin in each group
|
From the first day receiving cisplatin until two days after cisplatin in each group
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Global assessment on effectiveness by patients (a single direct question with five levels of alternatives)
Time Frame: The second day after cisplatin
|
The second day after cisplatin
|
|
Patients' confidence towards acupuncture treatment (a single direct question with five levels of alternatives)
Time Frame: The first day receiving cisplatin and the second day after cisplatin
|
The first day receiving cisplatin and the second day after cisplatin
|
|
Consumption of additional antiemetic
Time Frame: From the first day receiving cisplatin until two days after cisplatin
|
From the first day receiving cisplatin until two days after cisplatin
|
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Acupuncture related adverse events
Time Frame: From the first day receiving cisplatin until two days after cisplatin
|
From the first day receiving cisplatin until two days after cisplatin
|
|
Adverse events
Time Frame: From the first day receiving cisplatin until two days after cisplatin
|
From the first day receiving cisplatin until two days after cisplatin
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Primary Completion (Actual)
December 1, 2012
Study Completion (Actual)
December 1, 2012
Study Registration Dates
First Submitted
July 16, 2016
First Submitted That Met QC Criteria
July 20, 2016
First Posted (Estimate)
July 22, 2016
Study Record Updates
Last Update Posted (Estimate)
July 22, 2016
Last Update Submitted That Met QC Criteria
July 20, 2016
Last Verified
July 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EBM@BUCM-2
- 30901929 (Other Grant/Funding Number: National Natural Science)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chemotherapy-induced Nausea and Vomiting
-
GlaxoSmithKlineCompletedChemotherapy-Induced Nausea and Vomiting | Nausea and Vomiting, Chemotherapy-InducedTaiwan, United States, Germany, Russian Federation, Spain, Ireland, Thailand, Hong Kong, Mexico, Philippines, Austria, Chile, Greece, Poland, Canada, Czech Republic, United Kingdom, Hungary, Pakistan, Slovakia, Singapore, Portugal, ... and more
-
Blokhin's Russian Cancer Research CenterRUSSCO/RakFondUnknownChemotherapy-induced Nausea and Vomiting | Nausea | Vomiting | Emesis | Nausea Post ChemotherapyRussian Federation
-
Otolith LabsDrexel University College of MedicineWithdrawnChemotherapy-induced Nausea and Vomiting | Nausea Post ChemotherapyUnited States
-
Indonesia UniversityMashhad University of Medical SciencesCompletedChemotherapy-induced Nausea and Vomiting | Chemotherapy Effect | Pediatric CancerIndonesia
-
Joseph MaTerminatedChemotherapy Induced Nausea Vomiting
-
Simon Williamson ClinicHelsinn Healthcare SARecruitingChemotherapy Induced Nausea and VomitingUnited States
-
Antje KollerUniversity Medical Center Freiburg; ZETUP St. Gallen; Dr.-Hans-Altschüler-Sti... and other collaboratorsCompletedChemotherapy-induced Nausea and VomitingSwitzerland
-
Albert Einstein College of MedicineJacobi Medical CenterTerminatedChemotherapy-induced Nausea and VomitingUnited States
-
Purdue Pharma, CanadaCompletedChemotherapy-Induced Nausea and VomitingCanada
-
UNC Lineberger Comprehensive Cancer CenterUniversity of North Carolina, Chapel HillCompletedChemotherapy-induced Nausea and VomitingUnited States
Clinical Trials on Manual acupuncture implemented by senior acupuncturists
-
Beijing University of Chinese MedicineXiyuan Hospital of China Academy of Chinese Medical SciencesCompletedChemotherapy-induced Nausea and VomitingChina